The FDA granted orphan designation to Janssen Research & Development’s bleximenib as a treatment of acute myeloid leukemia, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Is Johnson & Johnson (NYSE:JNJ) a Worthwhile Dividend Stock?
- Johnson & Johnson price target lowered to $159 from $162 at Goldman Sachs
- Johnson & Johnson price target raised to $181 from $178 at RBC Capital
- Johnson & Johnson price target raised to $175 from $169 at Morgan Stanley
- Johnson & Johnson price target raised to $185 from $180 at Citi
